Mitral Valve Prolapse
Background
Mitral valve prolapse (MVP) is a prevalent heart condition characterized by the abnormal displacement of the mitral valve leaflets into the left atrium during ventricular systole. [1] This condition affects approximately 1 in 40 individuals in the general population. [1] The mitral valve plays a critical role in maintaining unidirectional blood flow within the heart, and its complex structure develops early in cardiac morphogenesis. [1]
Biological Basis
MVP is understood to have a polygenic basis, meaning that multiple genetic variants collectively influence an individual's susceptibility to the condition. [2] Research indicates that disease risk is modulated through changes in transforming growth factor-β (TGF-β) signaling, the cytoskeleton, and cardiomyopathy pathways. [2] Genetic studies have underscored the importance of genes involved in normal valve and cardiac development. [1] For example, mutations in genes such as FLNA have been linked to familial cardiac valvular dystrophy. [3] The proper organization of the extracellular matrix and the function of primary cilia are also crucial, with defects in these processes contributing to the progressive myxomatous degeneration of the mitral valve in both mice and humans. [1] Genome-wide association studies (GWAS) have identified numerous genetic loci associated with MVP, implicating candidate genes like TNS1, which plays a role in cell adhesion and cytoskeleton organization. [2] Other implicated genes include TGFB2, DIRC3, ZNF592, ALPK3, and DCHS1. [2]
Clinical Relevance
The degenerative process associated with MVP can lead to the valve's inability to close completely, resulting in mitral regurgitation. [1] Severe mitral regurgitation often necessitates surgical intervention, such as repair or replacement, due to its association with an increased risk of serious complications, including heart failure, arrhythmias, and sudden death. [1] Advances in genetic research are enhancing the understanding and prediction of MVP. Polygenic risk scores (PRS), which integrate the cumulative effects of many genetic variants, have shown promise in improving MVP risk prediction. These scores are particularly effective when combined with traditional clinical risk factors such as age, sex, hypertension, heart failure, diabetes, and myocardial infarction. [2] Individuals in the top 20% of PRS have a significantly increased odds ratio for MVP, highlighting the utility of these scores in identifying high-risk individuals. [2] Furthermore, MVP has demonstrated a shared genetic architecture with other cardiac conditions, including atrial fibrillation and heart failure. [2]
Social Importance
Given its commonality and the potential for severe health complications, understanding the genetic basis of MVP holds significant social importance. Identifying the underlying causal pathways and improving risk prediction through tools like PRS can facilitate earlier diagnosis, enable more targeted interventions, and potentially prevent adverse outcomes. [2] This genetic insight also contributes to a broader knowledge of cardiovascular biology and disease, offering a translational perspective for the development of novel therapeutic strategies.
Generalizability and Cohort Specificity
The genetic findings for mitral valve prolapse (MVP) are primarily derived from studies focused on populations of European ancestry, which inherently limits their direct generalizability to individuals from other ethnic backgrounds. While some trans-ancestry analyses for related traits like mitral valve annular diameter have identified novel loci in African/Afro-Caribbean populations, candidate signals in South and East Asian populations often did not meet significance thresholds, underscoring the need for more diverse cohorts to fully capture the global genetic architecture of MVP. [4] This ancestral bias means that the identified genetic variants and derived polygenic risk scores (PRS) may not accurately reflect risk or biological pathways in non-European populations, potentially hindering equitable clinical application.
Furthermore, some analyses, particularly sensitivity analyses, have been conducted on specific subsets of MVP patients, such as those who underwent mitral valve surgery. [2] While valuable for identifying severe forms of the disease, findings from such cohorts may not be fully representative of the broader MVP patient population, which includes individuals with milder forms who do not require surgical intervention. This potential for cohort bias could lead to an overemphasis on genetic factors relevant to more severe disease manifestations, limiting the applicability of findings to the full spectrum of MVP.
Phenotypic Complexity and Measurement Precision
The phenotypic definition of mitral valve prolapse itself presents a challenge, as it is a heterogeneous condition that can range from mild to severe, and its diagnosis often relies on imaging criteria. Although studies explicitly exclude rheumatic MVP, focusing on non-rheumatic forms, the underlying variability within non-rheumatic MVP can still influence genetic associations. [4] Precise characterization of MVP morphology and function remains crucial, with current approaches, such as simple 2D measurements of mitral annular diameter, potentially introducing systematic errors or failing to capture the full anatomical complexity of the valve apparatus. [4]
These measurement limitations can impact the power and interpretability of genetic studies, as less precise phenotyping may obscure true genetic signals or introduce noise. Moreover, measurements taken from the general population might reflect a blend of environmental stress-induced changes and early pathological remodeling, making it difficult to disentangle the primary genetic influences from secondary factors. [4] Future research would benefit from advanced imaging techniques and more direct measures of valve function to provide a richer anatomical substrate for genetic interrogation.
Incomplete Genetic Architecture and Environmental Influences
Despite identifying multiple genetic loci, the current understanding of MVP's genetic architecture remains incomplete, as evidenced by the observed SNP heritability on the liability scale, which suggests a substantial portion of heritability is yet to be explained by common genetic variants. [2] This "missing heritability" indicates that other genetic factors, such as rare variants, structural variations, or complex gene-gene interactions, likely play a significant, yet uncharacterized, role in MVP susceptibility. Further research is needed to comprehensively map these additional genetic contributions.
Beyond genetics, environmental factors and complex gene-environment interactions are recognized as important, though often unquantified, contributors to MVP development. For instance, environmental stressors can induce changes to the mitral valve annulus, potentially confounding genetic associations. [4] The interplay between an individual's genetic predisposition and their environment is not fully elucidated, representing a significant knowledge gap that impacts the comprehensive understanding of disease etiology and the development of preventive strategies. Addressing these complex interactions is essential for a holistic view of MVP risk.
The predictive power of polygenic risk scores (PRS) for MVP, while statistically significant, is currently moderate when used alone (AUC = 0.5838), and its contribution to predictive models is more pronounced when combined with established clinical factors like age and sex. [2] This suggests that while PRS can enhance risk prediction, they are not yet standalone diagnostic or prognostic tools, highlighting the need for further refinement and integration with a broader array of clinical, lifestyle, and environmental data to achieve higher predictive accuracy and clinical utility.
Variants
Genetic variants play a significant role in the predisposition to mitral valve prolapse (MVP), a condition characterized by the abnormal thickening and displacement of a mitral valve leaflet into the left atrium during systole. The ZNF592 and ALPK3 genes are notably associated with MVP through the sentinel variant rs35828350, which demonstrates a strong genome-wide significant association with the condition. [2] ALPK3 (Alpha-kinase 3) is a kinase involved in cell signaling pathways and has been identified as a candidate causal gene for MVP, potentially influencing gene expression in cardiac tissues and having detectable protein expression in human mitral valve tissue. [2] This variant has also been linked to other neurological traits such as autism and schizophrenia, suggesting potential pleiotropic effects or shared biological pathways. [2]
Another significant locus for MVP involves the BAG3 gene, with the variant rs17099139 showing a strong association. [2] BAG3 (BCL2-associated athanogene 3) is a cochaperone protein involved in protein folding, quality control, and stress response, particularly in muscle cells, and its dysfunction can contribute to cardiomyopathy, a condition that can overlap with MVP. [4] rs17099139 is also associated with mitral valve annular diameter, indicating its influence on the structural integrity and function of the valve. [4] The long intergenic non-coding RNA LINC02869 is implicated through rs12406058, a variant associated with MVP. [2] While the precise mechanism of LINC02869 in MVP is still being elucidated, long non-coding RNAs can regulate gene expression critical for cardiac development and function. Similarly, variants in the TESHL gene, including rs13399995, rs34909633, and rs12465515, are associated with MVP, with rs13399995 being a previously reported lead variant. [2] TESHL is located near TNS1 (Tensin 1), a gene whose protein product is critical for cell adhesion, migration, and cytoskeleton organization, processes essential for valve development and maintenance. [5] The polygenic nature of MVP means that many genetic variants collectively influence disease predisposition. [2]
Further genetic insights into MVP come from variants like rs55674920, which is associated with MVP and located near DHX8 and MEOX1. [2] MEOX1 (Mesenchyme Homeobox 1) is a transcription factor crucial for embryonic development, including cardiac and skeletal muscle formation, suggesting its role in valve morphogenesis. Variants rs888414 and rs11852134 are linked to LTBP2 and AREL1. [2] LTBP2 (Latent Transforming Growth Factor Beta Binding Protein 2) is vital for the assembly and regulation of the extracellular matrix, particularly in the context of TGF-β signaling, a pathway known to be critical for heart valve development and often implicated in connective tissue disorders that contribute to MVP. [1] The ERCC4 gene, along with LINC02185, is associated with MVP via rs13334552. [2] ERCC4 (Excision Repair Cross-Complementation Group 4) is involved in DNA repair and maintaining genomic stability, and its impact on rapidly developing tissues like heart valves could influence their structural integrity.
Other genetic loci also contribute to the complex etiology of MVP. Variants such as rs57355895, linked to RPS10P21 and RPL18AP17, are associated with MVP. [2] These genes are pseudogenes of ribosomal proteins, and while their direct functional role in MVP is less clear, they may influence gene regulation or be in linkage disequilibrium with other functional elements. Similarly, rs34871776, associated with TMEM40 and KRT18P17, has been identified in genome-wide association studies for MVP. [2] TMEM40 (Transmembrane Protein 40) is a gene with an unknown function but may play a role in cellular processes relevant to cardiac tissue. Furthermore, variants rs112258894 and rs216205 in SMG6 are associated with MVP. SMG6 (SMG6 nonsense mediated mRNA decay factor) is involved in mRNA surveillance and degradation, a process critical for regulating gene expression and ensuring proper protein synthesis, which can impact the development and health of heart valves. The cumulative effect of these genetic variations highlights the polygenic architecture of MVP, where multiple genes and pathways contribute to disease susceptibility. [2]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs35828350 | ZNF592 - ALPK3 | autism spectrum disorder, schizophrenia mitral valve prolapse |
| rs112258894 rs216205 |
SMG6 | mitral valve prolapse |
| rs12406058 | LINC02869 | mitral valve prolapse |
| rs17099139 | BAG3 | hypertrophic cardiomyopathy mitral valve prolapse cysteine and glycine-rich protein 3 measurement mitral valve annular diameter Antihypertensive use measurement |
| rs13399995 rs34909633 rs12465515 |
TESHL | mitral valve prolapse |
| rs55674920 | DHX8 - MEOX1 | mitral valve prolapse |
| rs888414 rs11852134 |
LTBP2 - AREL1 | level of latent-transforming growth factor beta-binding protein 2 in blood mitral valve prolapse body height |
| rs13334552 | ERCC4 - LINC02185 | mitral valve prolapse |
| rs57355895 | RPS10P21 - RPL18AP17 | mitral valve prolapse |
| rs34871776 | TMEM40 - KRT18P17 | mitral valve prolapse |
Mitral Valve Prolapse: Definition and Core Characteristics
Mitral valve prolapse (MVP) is a degenerative condition characterized by the abnormal displacement of one or both mitral valve leaflets into the left atrium during ventricular systole, often leading to mitral regurgitation. [4] This structural anomaly compromises the precise balance of force required for unidirectional blood flow through the mitral orifice, which is normally maintained by the complex, two-leaflet structure of the mitral valve. [1] The adult valve can lose its flexibility under permanent mechanical stress, initiating a degenerative process that results in prolapse. [1] MVP is understood to have a polygenic basis, meaning numerous genetic variants cumulatively influence an individual's predisposition to the disease, with risk potentially modulated through pathways such as transforming growth factor-β signaling, the cytoskeleton, and cardiomyopathy-related mechanisms. [2]
Diagnostic Criteria and Measurement Approaches
The diagnosis of idiopathic mitral valve prolapse in adults typically relies on consensus inclusion criteria, specifically the two-dimensional (2D) echocardiographic visualization of any part of the mitral valve leaflet(s) displacing ≥ 2 mm beyond a line connecting the annular hinge points in the parasternal long-axis view of the left ventricle. [3] For patients with a history of severe mitral regurgitation due to MVP who have undergone surgery, diagnosis can be confirmed by an operative report and written confirmation from the surgeon. [3] Importantly, MVP associated with other heart conditions like coronary artery disease with papillary muscle disruption, hypertrophic cardiomyopathy, or rheumatic disease, or known syndromes such as Marfan and Ehlers-Danlos, are generally excluded from idiopathic MVP diagnoses. [3] Furthermore, the size of the mitral annulus significantly influences MVP risk, and automated estimates of mitral valve annular diameter, derived from cardiac MRI images, serve as important measurement approaches in both research and clinical contexts. [4] Diagnostic codes, such as ICD-10 code I34, are also used for identifying MVP cases in large datasets. [4]
Classification and Genetic Risk Stratification
Mitral valve prolapse can be broadly classified based on its etiology, distinguishing between familial non-syndromic cases and those associated with rare syndromes like Marfan, Loeys-Dietz, and Ehlers-Danlos, where causal genes play key roles in extracellular matrix deposition and organization, often influenced by TGF beta and/or ciliogenic signaling. [1] The disease's polygenic nature supports a dimensional approach to risk assessment, where polygenic risk scores (PRS) can significantly enhance prediction of MVP. [2] For instance, individuals in the top 20% quintile of a PRS for MVP demonstrated an odds ratio of 1.79 compared to the bottom 80%, illustrating how continuous genetic risk can be stratified into categorical risk groups. [2] Genetic correlation analyses reveal shared genetic architecture between MVP and other cardiovascular phenotypes, including atrial fibrillation, heart failure, non-ischemic cardiomyopathy, and specific ECG and cardiac MRI traits, highlighting its nosological connections within cardiac health. [2] Genetic loci associated with MVP include regions near TNP1, DIRC3, TNS1, LMCD1, GLIS1, and mutations in the gene encoding FILAMIN A . [1], [2], [3]
Clinical Presentation and Associated Conditions
Mitral valve prolapse (MVP) is characterized by a degenerative process where the mitral valve leaflets lose flexibility and bulge into the left atrium during cardiac systole. [1] This prolapse can lead to mitral regurgitation, causing blood to flow backward through the valve. [1] The condition presents across a broad phenotypic spectrum, with some individuals exhibiting only mild expression. [6]
While direct symptomatic complaints are varied, MVP is genetically correlated with several significant cardiovascular phenotypes, suggesting potential clinical manifestations or complications. These include Atrial Fibrillation, Heart Failure, and Non-Ischemic Cardiomyopathy. [2] Furthermore, studies linking polygenic risk scores for mitral valve annular diameter have shown associations with ventricular tachycardia and varicose veins, which may present as clinical correlates or symptoms of MVP. [1] MVP is also recognized for its association with systemic abnormalities of connective tissue, forming a continuum with conditions like Marfan, Loeys-Dietz, and Ehlers-Danlos syndromes . [1], [7]
Diagnostic Assessment and Measurement
The diagnosis and evaluation of mitral valve prolapse (MVP) incorporate various objective measurement approaches, particularly cardiac imaging and genetic tools. Cardiac Magnetic Resonance Imaging (MRI) is used to derive automated measures of mitral valve annular diameter during both systole and diastole, offering crucial insights into valve function and biology. [1] These imaging-derived phenotypes are fundamental for genetic and clinical research, often utilizing deep-learning algorithms for precise segmentation and measurement. [1]
Beyond imaging, electrocardiographic (ECG) traits such as heart rate and PR interval show genetic correlations with MVP, indicating their potential utility as diagnostic or prognostic markers. [2] Genetic risk assessment, particularly through polygenic risk scores (PRS), is also emerging as a diagnostic aid. A PRS for mitral valve annular diameter can predict MVP across different cohorts. [1] Moreover, a PRS specifically for MVP, when integrated into a prediction model alongside age, sex, and established clinical risk factors like hypertension, heart failure, diabetes, and myocardial infarction, significantly enhances the accuracy of MVP risk prediction. [2]
Variability and Predictive Factors
The clinical presentation and risk profile of mitral valve prolapse (MVP) exhibit notable inter-individual variability and heterogeneity, influenced significantly by demographic factors such as age and sex. Research indicates that models incorporating age and sex possess considerable predictive power for MVP, which is further improved by the addition of a polygenic risk score (PRS). [2] This underscores that the manifestation and progression of MVP are not uniform across individuals but are modulated by these demographic characteristics. [2]
Genetic predisposition is a key determinant of this variability, as MVP has a polygenic basis, meaning numerous genetic variants collectively contribute to disease susceptibility. [2] The underlying genetic risk may be influenced by pathways involving transforming growth factor-β signaling, the cytoskeleton, and cardiomyopathy. [2] The complex interaction of these genetic factors with age, sex, and other clinical risk factors such as hypertension, heart failure, diabetes, and myocardial infarction contributes to the diverse phenotypic spectrum and impacts the overall risk prediction for MVP. [2]
Causes of Mitral Valve Prolapse
Mitral valve prolapse (MVP) is a complex condition characterized by the abnormal displacement of mitral valve leaflets into the left atrium during systole. Its etiology is multifactorial, stemming from a combination of genetic predispositions, developmental anomalies, and the influence of other physiological conditions. Research, particularly through large-scale genome-wide association studies (GWAS), has significantly advanced the understanding of the underlying causal mechanisms.
Genetic Predisposition and Polygenic Risk
A substantial portion of mitral valve prolapse risk is attributed to genetic factors, operating primarily through a polygenic basis where numerous genetic variants cumulatively influence an individual's predisposition. [2] Recent genome-wide association studies have identified 16 genetic loci significantly associated with MVP, with 12 of these being novel discoveries. [2] These loci implicate candidate genes involved in critical cardiac pathways, such as LMCD1, SPTBN1, TGFB2, TNP1/DIRC3/TNS1, TMEM40/CAND2, DACH1/MZT1, LTBP2/AREL1, ZNF592/ALPK3, ERCC4/MKL2, ETV4/MEOX1, and ATXN2. [2] For instance, the A-allele of rs12713274 is associated with an increased risk for MVP and a corresponding decrease in SPTBN1 gene expression within atrial tissue. [2]
Beyond common variants, rare Mendelian forms of MVP are recognized in the context of syndromes such as Marfan, Loeys-Dietz, and Ehlers-Danlos, where specific causal genes disrupt extracellular matrix deposition and organization. [1] These syndromic forms often involve dysregulation of transforming growth factor-beta (TGF-β) or ciliogenic signaling pathways, highlighting the role of these fundamental biological processes in valve integrity. [1] The cumulative effect of common genetic variants can be quantified using a polygenic risk score (PRS), which significantly enhances MVP risk prediction; individuals in the top 20% of PRS quintiles exhibit an odds ratio of 1.79 for MVP compared to those in the bottom 80%. [2]
Developmental Origin and Molecular Pathways
The development of the mitral valve is a complex process that occurs early during heart morphogenesis, shortly after cardiac looping. [1] Genetic analyses have consistently highlighted the association of MVP with genes involved in heart valve and cardiac development, suggesting that errors or vulnerabilities during these formative stages can predispose individuals to the condition. [1] Specific biological pathways underlying MVP pathophysiology include the transforming growth factor-beta (TGF-β) signaling pathway, which is crucial for cell growth, differentiation, and extracellular matrix regulation, as well as components of the cellular cytoskeleton and pathways related to cardiomyopathy. [2]
Disruptions in these pathways can lead to structural abnormalities in the valve leaflets and supporting chordae tendineae, compromising their ability to maintain proper function. For example, defects in primary cilia, cellular organelles involved in various signaling pathways, have also been mechanistically linked to MVP. [1] Furthermore, research has begun to explore the intersection of genetic findings with epigenetic and proteomics data from mitral valve tissue, indicating that early life influences and alterations in gene expression regulation, such as DNA methylation or histone modifications, may play a role in valve development and subsequent MVP risk. [2]
Comorbidities and Age-Related Modifiers
While genetics lay a foundational risk for mitral valve prolapse, other physiological factors, including comorbidities and age, significantly modulate its expression and progression. Age and sex are important non-genetic predictors, with models incorporating these variables showing significantly improved predictive power for MVP. [2] This suggests that the cumulative impact of mechanical stress over time can contribute to the gradual degenerative process where the adult valve loses its flexibility, eventually leading to prolapse. [1]
Moreover, MVP shares a genetic architecture and exhibits genetic correlations with several other cardiovascular phenotypes, including atrial fibrillation, heart failure, non-ischemic cardiomyopathy, and certain electrocardiographic traits such as PR interval. [2] Clinical risk factors like hypertension, heart failure, diabetes, and myocardial infarction at baseline further enhance the predictive power of MVP models when combined with genetic risk scores, indicating their role as significant contributors or exacerbating factors. [2] These comorbidities may either share common underlying genetic susceptibilities or exert physiological stress that promotes the development or progression of MVP.
Biological Background of Mitral Valve Prolapse
Mitral valve prolapse (MVP) is a common heart valve disorder affecting approximately 1 in 40 individuals in the general population . The intricate shape and function of the mitral valve, crucial for maintaining unidirectional blood flow, depend on precise extracellular matrix (ECM) deposition and organization. [1] Genetic mutations implicated in rare syndromes like Marfan, Loeys-Dietz, and Ehlers-Danlos, as well as in familial non-syndromic MVP cases, underscore the critical role of ECM-related genes in the disease's etiology. [1]
The adult valve's progressive loss of flexibility and subsequent degeneration leading to prolapse is a consequence of these mild developmental or functional dysregulations. [1] For instance, the gene DCHS1, a member of the cadherin superfamily, is essential for cell alignment during valve development, and its proper function is vital for maintaining valve integrity. [1] Furthermore, the cooperative regulation by transcription factors such as Smad4 and Gata4 is indispensable for cardiac valve development, highlighting the profound impact of precise gene regulation on preventing MVP. [8]
Cellular Adhesion and Cytoskeletal Dynamics
The mechanical resilience and structural integrity of the mitral valve are intrinsically linked to robust cellular adhesion and a meticulously organized cytoskeleton. Genome-wide association studies (GWAS) have identified predisposition loci, particularly those near TNS1, that are involved in cell adhesion, thereby emphasizing the importance of these interactions for valve health. [1] The cytoskeleton, a dynamic network of protein filaments, provides essential mechanical support and mediates cellular responses to the continuous mechanical stresses experienced by heart valves, making its proper organization crucial for preventing degenerative changes in MVP. [2]
Disruptions in cytoskeletal components directly contribute to valve pathology, as evidenced by mutations in the gene encoding Filamin A that cause familial cardiac valvular dystrophy. [9] The protein Tensin1 exemplifies the complex regulatory mechanisms involved, requiring protein phosphatase-1alpha and the RhoGAP DLC-1 to orchestrate cell polarization, migration, and invasion. [5] These cellular processes are fundamental for valve tissue remodeling and repair, and their impairment can compromise the valve's ability to maintain structural and functional integrity under persistent hemodynamic loads.
Key Signaling Cascades and Transcriptional Regulation
Several crucial signaling cascades govern mitral valve development and maintenance, and their dysregulation is central to MVP pathogenesis. The Transforming Growth Factor-beta (TGF-beta) signaling pathway is a prominent regulator, significantly influencing the deposition and organization of the extracellular matrix in heart valves. [1] Aberrant TGF-beta signaling can lead to altered cellular proliferation and differentiation, with factors like Id2 and Id3 playing a role in defining these cellular responses to TGF-beta and bone morphogenetic protein, thereby impacting valve tissue homeostasis. [10]
Ciliogenic signaling nodes also exert critical control over valve development, as demonstrated by the progressive myxomatous degeneration observed in the mitral valves of mice and humans with primary cilia defects. [1] Furthermore, mechanosensitive pathways, including those involving mechanically activated Piezo channels, modulate valve development through the Yap1 and Klf2-Notch signaling axis. [11] This highlights the intricate interplay between mechanical forces and molecular pathways in shaping valve structure and function, where dysregulation within these interconnected networks can disturb the delicate balance of cellular processes, contributing to the pathological changes characteristic of MVP.
Genetic Architecture and Regulatory Landscape
Mitral valve prolapse is characterized by a polygenic basis, meaning its predisposition is influenced by the cumulative effects of numerous genetic variants. [2] Genome-wide association studies (GWAS) have been instrumental in identifying these susceptibility loci, with downstream analyses including eQTL lookups in heart tissue to assess the impact of variants on gene expression and potential missense variations. [2] The regulatory landscape further involves examining protein expression data from mitral valve tissue and RNA-Seq data from valve and heart tissues, providing comprehensive insights into how genetic variations translate into altered protein levels and functions. [2]
Understanding gene regulation in MVP also involves evaluating the overlap of genetic variants with open chromatin regions, identified through ATAC-Seq data, which indicates areas of active gene transcription. [2] Gene-set enrichment analyses have highlighted candidate genes such as SMG6, SRR, and ABCC3, whose expression in developing mouse hearts suggests a potential role in the myxomatous process of the mitral valve. [1] Additionally, GLIS1 has been suggested as a susceptibility gene for MVP, and specific loci have implicated genes like ZNF592, ALPK3, and ATXN2 in MVP risk, collectively underscoring the complex genetic and regulatory mechanisms driving the disease . [2], [4]
Genetic Risk Assessment and Early Identification
Mitral valve prolapse (MVP) has a significant polygenic basis, meaning numerous genetic variants cumulatively influence an individual's predisposition to the condition. [2] A polygenic risk score (PRS) for MVP can enhance the prediction of disease risk. When integrated with traditional clinical factors such as age and sex, the PRS significantly improves predictive power compared to models relying solely on age and sex. [2] Further incorporating clinical risk factors like hypertension, heart failure, diabetes, and myocardial infarction alongside the PRS offers even greater accuracy in MVP risk prediction, highlighting its utility in identifying high-risk individuals. [2] For instance, individuals in the top 20% of the PRS distribution have a nearly 1.8-fold increased odds of developing MVP compared to those in the bottom 80%, demonstrating the PRS's potential for early risk stratification. [2]
Beyond direct MVP risk, a polygenic score derived from automated measurements of mitral valve annular diameter (MVAD) from cardiac MRI is also predictive of MVP and mitral valve regurgitation across different cohorts. [1] The polygenic score for MVAD measured during ventricular systole shows a particularly strong association, with a 1.19-fold increased risk of MVP per standard deviation increase in the score. [1] This suggests that genetic determinants of mitral valve anatomy and function can serve as early indicators, offering a pathway for personalized risk assessment and potentially informing prevention strategies before overt symptoms manifest. [1]
Pathophysiological Insights and Associated Conditions
Genetic analyses reveal that the risk for mitral valve prolapse is intricately linked to alterations in key biological pathways, including transforming growth factor-beta (TGF-β) signaling, cytoskeletal regulation, and cardiomyopathy-related processes. [2] Genes crucial for normal valve and cardiac development are consistently found to be associated with MVP, underscoring the developmental origins of the disease. [1] These genetic influences often impact extracellular matrix deposition and organization, with significant modulation by TGF-β and ciliogenic signaling nodes. [1] Such insights into the underlying pathophysiology can help explain disease progression and inform the development of novel therapeutic targets.
MVP exhibits genetic correlations with several other cardiovascular conditions, suggesting shared genetic predispositions and overlapping phenotypes. [2] Notably, genetic links have been identified with atrial fibrillation, heart failure, non-ischemic cardiomyopathy, and specific electrocardiographic traits such as heart rate and PR interval. [2] These correlations imply common genetic architectures that contribute to the pathogenesis of multiple cardiac disorders. Furthermore, MVP is recognized as part of a broader spectrum of connective tissue disorders, presenting as a phenotypic continuum with systemic abnormalities seen in rare syndromic presentations like Marfan, Loeys-Dietz, and Ehlers-Danlos syndromes, as well as in familial non-syndromic cases. [1] A polygenic risk score for mitral valve annular diameter has also shown positive associations with varicose veins and ventricular tachycardia, alongside an inverse association with type 2 diabetes, further highlighting the systemic connections of MVP. [1]
Prognostic Implications and Monitoring Strategies
The identification of a polygenic basis and specific genetic loci associated with MVP, including rs13399995 near TNP1/DIRC3/TNS1 and *rs165177_ near LMCD1, provides crucial insights into the causal pathways of the disease. [2] This genetic understanding holds prognostic value by potentially predicting long-term outcomes and disease progression in individuals. For instance, the genetic correlations observed between MVP and conditions like heart failure and non-ischemic cardiomyopathy suggest that patients with a strong genetic predisposition to MVP may be at an elevated risk for these complications, necessitating proactive monitoring. [2]
Such genetic insights can facilitate personalized medicine approaches, allowing clinicians to identify individuals who may benefit from more intensive monitoring or earlier interventions. While the overall predictive power of the PRS for MVP is moderate, its incremental value when combined with established clinical risk factors supports its role in refining risk stratification and guiding monitoring strategies, especially in those with subtle forms of MVP or a family history. [2] Continued research into the genetic underpinnings of MVP, particularly concerning variants affecting cellular alignment, ciliary function, and TGF-β signaling, promises to uncover new avenues for targeted treatments and improved patient care. [1]
Frequently Asked Questions About Mitral Valve Prolapse
These questions address the most important and specific aspects of mitral valve prolapse based on current genetic research.
1. If my parent has MVP, will I get it too?
MVP has a polygenic basis, meaning many different genes contribute to your risk, not just one. While some genetic variants are linked to familial forms of MVP, it's not a simple "yes or no" inheritance. Your risk is increased if a parent has it, but other genetic factors and how they interact also play a role in whether you develop the condition.
2. Can I prevent MVP if it runs in my family?
MVP is primarily driven by genetic factors that influence how your heart valve develops and functions. While you can't change your genetic predisposition, maintaining a heart-healthy lifestyle, including managing blood pressure and diabetes, can help reduce the risk of complications if you do develop MVP. Early detection and monitoring are also very important.
3. Would a DNA test help understand my MVP risk?
Yes, polygenic risk scores (PRS) are being developed that integrate the effects of many genetic variants to predict MVP risk. These scores have shown promise in identifying individuals at higher risk, especially when combined with traditional clinical factors like age and other health conditions. This information could potentially guide earlier monitoring or targeted interventions.
4. If I have MVP, will I need heart surgery?
Not necessarily. MVP can range significantly in severity. While severe cases, particularly those leading to significant mitral regurgitation, often require surgery to prevent serious complications like heart failure or arrhythmias, many individuals with MVP experience mild symptoms and never need surgical intervention. Your specific condition and progression will determine the need for surgery.
5. Does my ethnic background affect my MVP chance?
Yes, most genetic findings for MVP are based on studies of people of European ancestry. This means that the identified genetic variants and polygenic risk scores may not accurately reflect risk or biological pathways in individuals from other ethnic backgrounds, such as South or East Asian populations. More diverse research is needed to understand these differences globally.
6. Is my MVP linked to other heart problems?
Yes, MVP has a shared genetic architecture with other common cardiac conditions, including atrial fibrillation and heart failure. This means that some of the same genetic pathways that contribute to MVP might also increase your susceptibility to these other heart issues. Understanding these connections helps in a more complete assessment of your overall heart health.
7. Why do some people's heart valves just go wrong?
It often comes down to genetic instructions influencing the development and structure of your mitral valve. Multiple genes contribute to the proper organization of the extracellular matrix, the cytoskeleton, and important signaling pathways like TGF-β. Defects in these genetic processes can lead to the progressive weakening and abnormal displacement of the valve over time.
8. Should I avoid activities with severe MVP risk?
If you have a known genetic risk for severe MVP or have been diagnosed with it, it's crucial to follow your doctor's advice on activity levels. While mild MVP usually doesn't restrict daily life, severe cases can lead to complications that might require adjustments to avoid overstressing your heart. Regular medical monitoring will help guide these decisions for you.
9. Do diet or stress make my MVP worse?
The primary cause of MVP is genetic, affecting how your heart valve develops. There's no direct evidence that specific diets or stress levels cause MVP or directly worsen the valve prolapse itself. However, maintaining a heart-healthy lifestyle and managing stress is always beneficial for overall cardiovascular health, which is important if you have MVP.
10. Why did I get MVP, but my sibling didn't?
MVP has a polygenic basis, meaning many different genetic variants contribute to the risk, not just one. You and your sibling inherit different combinations of these variants from your parents. Even with similar genetic backgrounds, subtle differences in these combinations, along with other factors, can lead to one sibling developing MVP and the other not.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Yu M, et al. Genome-Wide Association Meta-Analysis Supports Genes Involved in Valve and Cardiac Development to Associate With Mitral Valve Prolapse. Circ Genom Precis Med. 2021; 14(4):e003442.
[2] Roselli C, et al. Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse. Eur Heart J. 2022; 43(15):1481–1493.
[3] Dina, C., et al. "Genetic association analyses highlight biological pathways underlying mitral valve prolapse." Nat Genet, vol. 47, no. 9, 2015, pp. 1018-24. PMID: 26301497.
[4] Yu M, et al. Computational estimates of annular diameter reveal genetic determinants of mitral valve function and disease. JCI Insight. 2022; 7(3):e146580.
[5] Hall EH, Daugherty AE, Choi CK, Horwitz AF, Brautigan DL. Tensin1 requires protein phosphatase-1alpha in addition to RhoGAP DLC-1 to control cell polarization, migration, and invasion. J Biol Chem. 2009; 284:34713–22.
[6] Delling, F. N., et al. "Mild expression of mitral valve prolapse in the Framingham offspring: expanding the phenotypic spectrum." J Am Soc Echocardiogr, vol. 27, 2014, pp. 17–23. PMID: 24200742.
[7] Glesby, M. J., and Pyeritz, R. E. "Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum." JAMA, vol. 262, no. 4, 1989, pp. 523–8. PMID: 2739055.
[8] Moskowitz, Ian P., et al. "Transcription factor genes Smad4 and Gata4 cooperatively regulate cardiac valve development." Proceedings of the National Academy of Sciences, vol. 102, no. 50, 2005, pp. 18071–18076.
[9] Kyndt, Florence, et al. "Mutations in the Gene Encoding Filamin A as a Cause for Familial Cardiac Valvular Dystrophy." Circulation, vol. 115, no. 1, 2007, pp. 40–49.
[10] Kowanetz, Monika, et al. "Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein." Molecular and Cellular Biology, vol. 24, no. 10, 2004, pp. 4241–4254.
[11] Duchemin, Anne-Laure, et al. "Mechanically activated piezo channels modulate outflow tract valve development through the Yap1 and Klf2-Notch signaling axis." eLife, vol. 8, 2019, e43322.